Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1032)	2/9/2004 9:39:49 AM
From: nigel bates	Read Replies (1) \| Respond to of 1139

This is anecdotal ? <g>

To: scaram(o)uche who wrote (1032)	2/9/2004 11:13:54 AM
From: Ian@SI	Read Replies (1) \| Respond to of 1139

Why? Do you suspect the ad warning about the priapism side effect was a marketing coup.<g> I'm surprised the FDA let them mention that side effect!

To: scaram(o)uche who wrote (1032)	2/10/2004 9:50:17 PM
From: tom pope	Read Replies (1) \| Respond to of 1139

I was surprised to find that Viagra is not that important in the overall PFE line-up (revenues, not necessarily profits). This from my ML guy:(he said proposes when he meant purposes, not me.) According to S&P, copy is in the mail for compliance proposes: "We expect 2004 sales to climb 16%, exceeding $52 billion, Viagra $1.9 billion Lipator 9.2 billion Norvasc 4.3 billion Celebrex/Bestra 2.6 billion Zyrtec 1.3 billion Zoloft 3.1 billion Neurontin 2.7 billion..."